Certara, Inc. (CERT) stock: key figures, P/E, revenue and dividend
Information Technology · United States · ISIN US15687V1098
Certara, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 418.84 m USD |
| Gross profit | 257.71 m USD |
| Operating income | 21.02 m USD |
| EBIT | 27.35 m USD |
| Net income | -1.60 m USD |
| Diluted EPS – continuing operations | -0.01 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Certara, Inc.
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
More stocks
- OMNICELL, INC. (OMCL)
- Soulbrain Co. Ltd (357780.KQ)
- Douglas Emmett Inc (DEI)
- TRICO BANCSHARES / (TCBK)
- F&F Co Ltd (383220.KS)
- Ningbo Haitian Precision Machinery Co Ltd (601882.SS)
- Sally Beauty Holdings, Inc. (SBH)
- Tecnoglass Holdings Inc. (TGLS)
- Zhejiang Runtu Co Ltd (002440.SZ)
- Ningbo ZhongDa Leader Intelligent Transmission Co Ltd (002896.SZ)
- Austevoll Seafood ASA (AUSS.OL)
- Vivendi SE (VIV.PA)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.